This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Study in Subjects With Perennial Allergic Rhinitis

This study has been completed.
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp. Identifier:
First received: September 13, 2005
Last updated: January 22, 2016
Last verified: January 2016
The purpose of this study was to determine the efficacy and safety of the study drug compared to placebo for the treatment of subjects with perennial allergic rhinitis.

Condition Intervention Phase
Perennial Allergic Rhinitis Drug: INS37217 Nasal Spray Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Multi-Center, Randomized, Parallel-Group, Double-Blind, Efficacy and Safety Study of INS37217 Nasal Spray Versus Placebo in Subjects With Perennial Allergic Rhinitis

Further study details as provided by Merck Sharp & Dohme Corp.:

Primary Outcome Measures:
  • total nasal symptom score

Secondary Outcome Measures:
  • average total nasal symptom scores over various timepoints average individual symptom scores
  • global assessment of perennial allergic rhinitis symptoms
  • instantaneous assessment of symptoms
  • change from baseline in quality of life assessments
  • physical and anterior nasal exams
  • laboratory tests
  • ECG
  • vital signs
  • adverse events

Estimated Enrollment: 630
Study Start Date: December 2002
Study Completion Date: April 2003
Primary Completion Date: April 2003 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   Child, Adult, Senior

Inclusion Criteria:

  • Have a documented history of allergy to perennial allergens and demonstrated sensitivity by the results of prick or intradermal skin testing.
  • Have a self-reported history of at least mild, intermittent rhinorrhea and nasal blockage/stuffiness due to allergies.
  • Have not started or had a change in immunotherapy regimen.

Exclusion Criteria:

  • Have a physical obstruction in the nose.
  • Will likely have an acute increase in severity of allergic rhinitis due to seasonal aeroallergens during the trial.
  • Have acute or chronic sinusitis or had previous sinus surgery resulting in a significant change in the sinus or nasal anatomy.
  • Have rhinitis medicamentosa or any other acute or chronic condition that could confound evaluations of nasal symptoms.
  • Have asthma of sufficient severity to require use of excluded medications.
  • Have taken any medications excluded as listed in the protocol.
  • Have a clinically significant acute or chronic disease or clinically significant laboratory abnormality.
  • Are a current smoker, recent smoker or past smoker as defined in the protocol.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00210015

Sponsors and Collaborators
Merck Sharp & Dohme Corp.
Study Director: Amy Schaberg, B.S.N.
  More Information

Responsible Party: Merck Sharp & Dohme Corp. Identifier: NCT00210015     History of Changes
Other Study ID Numbers: 07-105
Study First Received: September 13, 2005
Last Updated: January 22, 2016

Additional relevant MeSH terms:
Rhinitis, Allergic
Rhinitis, Allergic, Perennial
Nose Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Otorhinolaryngologic Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases processed this record on September 21, 2017